New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Once‐daily deferasirox dispersible tablets (DT) have a well‐defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerabilit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Hematol
Autori principali: Taher, Ali T., Origa, Raffaella, Perrotta, Silverio, Kourakli, Alexandra, Ruffo, Giovan Battista, Kattamis, Antonis, Goh, Ai‐Sim, Cortoos, Annelore, Huang, Vicky, Weill, Marine, Merino Herranz, Raquel, Porter, John B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585741/
https://ncbi.nlm.nih.gov/pubmed/28142202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24668
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi